Replies to post #157016 on Biotech Values

[genisi]

Dolutegravir will take share from Isentress in treatment-experienced patients but as you said, its combo with Epzicom isn't an attractive option to Stribild in first line. Still, Isentress annual sales were about $1.5B last year.